BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 19816013)

  • 1. Mutagenicity of immunosuppressive medications among renal transplant recipients.
    Rath T; Oliveira-Frick V
    Am J Nephrol; 2009; 30(6):514-20. PubMed ID: 19816013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures.
    Oliveira VD; Zankl H; Rath T
    Exp Clin Transplant; 2004 Dec; 2(2):273-9. PubMed ID: 15859941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil.
    Ferraris JR; Ghezzi LF; Vallejo G; Piantanida JJ; Araujo JL; Sojo ET
    Pediatr Transplant; 2005 Apr; 9(2):178-82. PubMed ID: 15787789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
    Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
    Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell cancer after kidney transplantation.
    Kleine-Döpke D; Oelke M; Schwarz A; Schwager Y; Lehner F; Klempnauer J; Schrem H
    Langenbecks Arch Surg; 2018 Aug; 403(5):631-641. PubMed ID: 30003323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil-induced hyperbilirubinemia in renal transplant recipients.
    Chueh SC; Huang CY; Lai MK
    Transplant Proc; 2000 Nov; 32(7):1901-2. PubMed ID: 11119992
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs.
    Renders L; Steinbach R; Valerius T; Schöcklmann HO; Kunzendorf U
    Kidney Blood Press Res; 2004; 27(3):181-5. PubMed ID: 15256815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
    Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
    J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants].
    van Gelder T; Gregoor PJ; Hené RJ; De Sévaux RG; Hilbrands LB
    Ned Tijdschr Geneeskd; 1998 Jul; 142(27):1550-4. PubMed ID: 9763828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
    Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients.
    Sureshkumar KK; Nghiem DD
    Transplantation; 2003 Jul; 76(2):441-2. PubMed ID: 12883215
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
    Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.